Shares of Merus Labs International Inc (TSE:MSL) (NASDAQ:MSLI) have been assigned an average recommendation of “Buy” from the nine research firms that are covering the company. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is C$2.77.

MSL has been the topic of several recent research reports. TD Securities restated a “buy” rating and set a C$4.00 price target on shares of Merus Labs International in a report on Tuesday, August 16th. Scotiabank reduced their target price on Merus Labs International from C$2.25 to C$1.75 and set a “sector perform” rating on the stock in a research note on Tuesday, August 16th. CIBC reduced their target price on Merus Labs International from C$2.90 to C$2.50 in a research note on Tuesday, August 16th. Paradigm Capital reduced their target price on Merus Labs International from C$1.75 to C$1.60 and set a “hold” rating on the stock in a research note on Tuesday, October 4th. Finally, Canaccord Genuity reduced their target price on Merus Labs International from C$4.25 to C$3.50 and set a “buy” rating on the stock in a research note on Tuesday, August 16th.

Shares of Merus Labs International (TSE:MSL) traded up 1.60% on Tuesday, hitting $1.27. 116,383 shares of the company traded hands. Merus Labs International has a 1-year low of $1.14 and a 1-year high of $2.40. The firm’s 50 day moving average price is $1.25 and its 200-day moving average price is $1.46. The stock’s market capitalization is $148.59 million.

ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The correct version of this article can be read at http://www.dailypolitical.com/2016/11/29/merus-labs-international-inc-msl-receives-average-rating-of-buy-from-analysts.html.

Merus Labs International Company Profile

Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.